Literature DB >> 6343858

Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history.

M H Brooke, G M Fenichel, R C Griggs, J R Mendell, R Moxley, J P Miller, M A Province.   

Abstract

A prospective study of 114 patients with DMD provided data for "power" calculations for future therapeutic trials. There was a decline in strength of 0.4 units per year (on a 0-10 scale). Contractures of the iliotibial bands, hip flexors, and heel cords developed before 6 years. Contractures of other joints accompanied the increased use of wheelchairs. All children walked until 8 years with functional "improvement" between 3-6 years. Children of the same age varied widely in their strength, degree of contracture, and functional abilities. Fifteen percent of the patients appear to have a milder variety of the disease and are termed "outliers." To test a drug which might slow the disease to 25% of its original rate of progression, two groups (placebo and treatment) of 40 patients each would have to be followed for one year.

Entities:  

Mesh:

Year:  1983        PMID: 6343858     DOI: 10.1002/mus.880060204

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  69 in total

Review 1.  Genetic and clinical correlations of Xp21 muscular dystrophy.

Authors:  K M Bushby
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophy.

Authors:  Christopher Spurney; Reiko Shimizu; Lauren P Morgenroth; Hanna Kolski; Heather Gordish-Dressman; Paula R Clemens
Journal:  Muscle Nerve       Date:  2014-05-14       Impact factor: 3.217

3.  Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers.

Authors:  C J Klein; D D Coovert; D E Bulman; P N Ray; J R Mendell; A H Burghes
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

Review 4.  Improved diagnosis of Duchenne/Becker muscular dystrophy.

Authors:  A H Beggs; L M Kunkel
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

5.  Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Authors:  Chad Heatwole; Rita Bode; Nicholas E Johnson; Jeanne Dekdebrun; Nuran Dilek; Katy Eichinger; James E Hilbert; Eric Logigian; Elizabeth Luebbe; William Martens; Michael P Mcdermott; Shree Pandya; Araya Puwanant; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard T Moxley
Journal:  Muscle Nerve       Date:  2015-12-29       Impact factor: 3.217

Review 6.  Update on the treatment of Duchenne muscular dystrophy.

Authors:  Louise R Rodino-Klapac; Jerry R Mendell; Zarife Sahenk
Journal:  Curr Neurol Neurosci Rep       Date:  2013-03       Impact factor: 5.081

Review 7.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

8.  Clinical heterogeneity of duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up.

Authors:  Isabelle Desguerre; Christo Christov; Michele Mayer; Reinhard Zeller; Henri-Marc Becane; Sylvie Bastuji-Garin; France Leturcq; Catherine Chiron; Jamel Chelly; Romain K Gherardi
Journal:  PLoS One       Date:  2009-02-05       Impact factor: 3.240

9.  Quantitative assessment of the T2 relaxation time of the gluteus muscles in children with Duchenne muscular dystrophy: a comparative study before and after steroid treatment.

Authors:  Hee Kyung Kim; Tal Laor; Paul S Horn; Brenda Wong
Journal:  Korean J Radiol       Date:  2010-04-29       Impact factor: 3.500

10.  Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial.

Authors:  Elise Mok; Guy Letellier; Jean-Marie Cuisset; André Denjean; Frédéric Gottrand; Corinne Alberti; Régis Hankard
Journal:  PLoS One       Date:  2009-05-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.